Aquestive Therapeutics (AQST) Receivables (2017 - 2025)
Historic Receivables for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $14.1 million.
- Aquestive Therapeutics' Receivables rose 2092.29% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 2092.29%. This contributed to the annual value of $9.8 million for FY2024, which is 1378.01% down from last year.
- Per Aquestive Therapeutics' latest filing, its Receivables stood at $14.1 million for Q3 2025, which was up 2092.29% from $14.1 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Receivables registered a high of $22.6 million during Q2 2022, and its lowest value of $6.8 million during Q4 2022.
- Its 5-year average for Receivables is $13.2 million, with a median of $12.7 million in 2025.
- Its Receivables has fluctuated over the past 5 years, first plummeted by 6223.51% in 2022, then skyrocketed by 8358.99% in 2025.
- Aquestive Therapeutics' Receivables (Quarter) stood at $18.1 million in 2021, then tumbled by 62.24% to $6.8 million in 2022, then soared by 66.39% to $11.4 million in 2023, then decreased by 13.78% to $9.8 million in 2024, then skyrocketed by 43.88% to $14.1 million in 2025.
- Its Receivables was $14.1 million in Q3 2025, compared to $14.1 million in Q2 2025 and $12.7 million in Q1 2025.